Unusual Presentation of Classical Galactosemia: A Case Report of Iranian Experience
Mohammadreza Alaee
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Supervision, Validation, Visualization
Search for more papers by this authorHedyeh Saneifard
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Supervision, Validation
Search for more papers by this authorMarjan Shakiba
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Supervision, Validation
Search for more papers by this authorMarjan Hanifeh
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Resources
Search for more papers by this authorCorresponding Author
Shirin Moarefian
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Department of Neurogenetics, Iranian Center of Neurological Research (ICNR), Tehran University of Medical Sciences, Tehran, Iran
Correspondence:
Shirin Moarefian ([email protected])
Contribution: Conceptualization, Data curation, Visualization, Writing - original draft
Search for more papers by this authorMohammadreza Alaee
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Supervision, Validation, Visualization
Search for more papers by this authorHedyeh Saneifard
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Supervision, Validation
Search for more papers by this authorMarjan Shakiba
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Supervision, Validation
Search for more papers by this authorMarjan Hanifeh
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Contribution: Resources
Search for more papers by this authorCorresponding Author
Shirin Moarefian
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Department of Neurogenetics, Iranian Center of Neurological Research (ICNR), Tehran University of Medical Sciences, Tehran, Iran
Correspondence:
Shirin Moarefian ([email protected])
Contribution: Conceptualization, Data curation, Visualization, Writing - original draft
Search for more papers by this authorFunding: The authors received no specific funding for this work.
ABSTRACT
Galactosemia is a rare autosomal recessive metabolic disorder with four main types, and classic galactosemia is the most prevalent. These patients have galactose-1-phosphate-uridyltransferase deficiency. We report on a case of an infant who was admitted with poor feeding, lethargy, and poor weight gain. Based on the clinical symptoms and laboratory findings, the patient was considered to have a metabolic disorder. The patient had unusual presentations such as macrocytic anemia requiring blood transfusions, repeatedly metabolic acidosis requiring bicarbonate therapy and failure to thrive in addition to neurodevelopmental delay which led the authors to different diagnoses and suspect to mitochondrial disorders. Finally, in one of the assessments before blood transfusion, a high galactose-1 phosphate was detected, and galactose-free diet was started which led to neurologic and physical of the child. The whole-exome sequencing (WES) also revealed a likely pathogenic homozygous mutation in GALT (c.794 C>G, p. Pro265Arg) confirming the diagnosis of classic galactosemia. In Iran, global neonatal metabolic screening is not done for galactosemia which results in late diagnosis of the affected patients. So, we suggest adding galactosemia to neonatal metabolic screening in Iran.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
Data available on request from the authorsData available on request due to privacy/ethical restrictions.
References
- 1R. B. Guerrero, D. Salazar, and P. Tanpaiboon, “Laboratory Diagnostic Approaches in Metabolic Disorders,” Annals of Translational Medicine 6, no. 24 (2018): 470, https://doi.org/10.21037/atm.2018.11.05.
- 2A. W. El-Hattab, “Inborn Errors of Metabolism,” Clinics in Perinatology 42, no. 2 (2015): 413–439, https://doi.org/10.1016/j.clp.2015.02.010.
- 3P. M. Campeau, C. R. Scriver, and J. J. Mitchell, “A 25-Year Longitudinal Analysis of Treatment Efficacy in Inborn Errors of Metabolism,” Molecular Genetics and Metabolism 95, no. 1 (2008): 11–16, https://doi.org/10.1016/j.ymgme.2008.07.001.
- 4A. Garrod, “The Incidence of Alkaptonuria: A Study in Chemical Individuality,” Lancet 160, no. 4137 (1902): 1616–1620, https://doi.org/10.1016/S0140-6736(01)41972-6.
10.1016/S0140-6736(01)41972-6 Google Scholar
- 5J. V. Leonard and A. A. M. Morris, “Diagnosis and Early Management of Inborn Errors of Metabolism Presenting Around the Time of Birth,” Acta Paediatrica 95, no. 1 (2006): 6–14, https://doi.org/10.1111/j.1651-2227.2006.tb02172.x.
- 6J. M. Saudubray and À. Garcia-Cazorla, “Inborn Errors of Metabolism Overview: Pathophysiology, Manifestations, Evaluation, and Management,” Pediatric Clinics of North America 65, no. 2 (2018): 179–208, https://doi.org/10.1016/j.pcl.2017.11.002.
- 7D. J. Timson, “The Molecular Basis of Galactosemia — Past, Present and Future,” Gene 589, no. 2 (2016): 133–141, https://doi.org/10.1016/j.gene.2015.06.077.
- 8I. Timmers, H. Zhang, M. Bastiani, B. M. Jansma, A. Roebroeck, and M. E. Rubio-Gozalbo, “White Matter Microstructure Pathology in Classic Galactosemia Revealed by Neurite Orientation Dispersion and Density Imaging,” Journal of Inherited Metabolic Disease 38, no. 2 (2015): 295–304, https://doi.org/10.1007/s10545-014-9780-x.
- 9N. L. Potter, Y. Nievergelt, and L. D. Shriberg, “ Motor and Speech Disorders in Classic Galactosemia,” in JIMD Reports, vol. 11, ed. J. Zschocke, K. M. Gibson, G. Brown, E. Morava, and V. Peters (Springer, 2013), 31–41, https://doi.org/10.1007/8904_2013_219.
10.1007/8904_2013_219 Google Scholar
- 10F. Conte, N. van Buuringen, N. C. Voermans, and D. J. Lefeber, “Galactose in Human Metabolism, Glycosylation and Congenital Metabolic Diseases: Time for a Closer Look,” Biochimica et Biophysica Acta (BBA) - General Subjects 1865, no. 8 (2021): 129898, https://doi.org/10.1016/j.bbagen.2021.129898.
- 11A. Von Reuss, “Zuckerausscheidung im Säuglingsalter,” Wiener Medizinische Wochenschrift (1946) 58 (1908): 799–801.
- 12A. I. Coelho, M. E. Rubio-Gozalbo, J. B. Vicente, and I. Rivera, “Sweet and Sour: An Update on Classic Galactosemia,” Journal of Inherited Metabolic Disease 40, no. 3 (2017): 325–342, https://doi.org/10.1007/s10545-017-0029-3.
- 13N. Karadag, A. Zenciroglu, F. Eminoglu, et al., “Literature Review and Outcome of Classic Galactosemia Diagnosed in the Neonatal Period,” Clinical Laboratory 59, no. 9–10 (2013): 1139–1146, https://doi.org/10.7754/Clin.Lab.2013.121235.
- 14V. Lewis, F. Welch, F. Cherry, E. Flood, and M. Marble, “Galactosemia: Clinical Features, Diagnosis and Management. A Case Report,” Journal of the Louisiana State Medical Society 147, no. 6 (1995): 262–265.
- 15G. T. Berry, “Galactosemia: When Is It a Newborn Screening Emergency?,” Molecular Genetics and Metabolism 106, no. 1 (2012): 7–11, https://doi.org/10.1016/j.ymgme.2012.03.007.
- 16G. T. Berry, Classic Galactosemia and Clinical Variant Galactosemia (University of Washington, 2021), accessed September 5, 2023, https://europepmc.org/article/NBK/nbk1518.
- 17A. M. Bosch, “Classical Galactosaemia Revisited,” Journal of Inherited Metabolic Disease 29, no. 4 (2006): 516–525, https://doi.org/10.1007/s10545-006-0382-0.
- 18E. Los and G. A. Ford, Galactose-1-Phosphate Uridyltransferase Deficiency (StatPearls Publishing, 2023), http://europepmc.org/books/NBK441957.
- 19Z. Kavehmanesh, M. Torkaman, and F. Beiraghdar, “A Case of Classic Galactosemia Manifesting as Neonatal Early and Profound Indirect Hyperbilirubinemia,” Turkish Archives of Pediatrics 55, no. 3 (2022): 316–319, https://doi.org/10.14744/turkpediatriars.2019.21298.
10.14744/turkpediatriars.2019.21298 Google Scholar
- 20S. Takci, S. Kadayifcilar, T. Coskun, S. Yigit, and B. Hismi, “A Rare Galactosemia Complication: Vitreous Hemorrhage,” JIMD Reports – Case and Research Reports 5 (2012): 89–93, https://doi.org/10.1007/8904_2011_103.
- 21L. Welling, L. E. Bernstein, G. T. Berry, et al., “International Clinical Guideline for the Management of Classical Galactosemia: Diagnosis, Treatment, and Follow-Up,” Journal of Inherited Metabolic Disease 40, no. 2 (2017): 171–176, https://doi.org/10.1007/s10545-016-9990-5.
- 22M. E. Rubio-Gozalbo, M. Haskovic, A. M. Bosch, et al., “The Natural History of Classic Galactosemia: Lessons From the GalNet Registry,” Orphanet Journal of Rare Diseases 14, no. 1 (2019): 86, https://doi.org/10.1186/s13023-019-1047-z.
- 23R. J. Pollitt, A. Green, M. C. CJ, et al., “Neonatal Screening for Inborn Errors of Metabolism: Cost, Yield and Outcome: A Review,” Health Technology Assessment 1, no. 7 (1997): i–iv, https://doi.org/10.3310/hta1070.
- 24S. Schweitzer-Krantz, “Early Diagnosis of Inherited Metabolic Disorders Towards Improving Outcome: The Controversial Issue of Galactosaemia,” European Journal of Pediatrics 162, no. 1 (2003): S50–S53, https://doi.org/10.1007/s00431-003-1352-2.
- 25V. Shah, S. Friedman, A. Moore, B. Platt, and A. Feigenbaum, “Selective Screening for Neonatal Galactosemia: An Alternative Approach,” Acta Paediatrica 90, no. 8 (2001): 948–949, https://doi.org/10.1111/j.1651-2227.2001.tb02463.x.
- 26S. E. Waisbren, C. Y. Read, M. Ampola, et al., “Newborn Screening Compared to Clinical Identification of Biochemical Genetic Disorders,” Journal of Inherited Metabolic Disease 25, no. 7 (2002): 599–600, https://doi.org/10.1023/A:1022003726224.
- 27J. H. Walter, “Arguments for Early Screening: A Clinician's Perspective,” European Journal of Pediatrics 162, no. 1 (2003): S2–S4, https://doi.org/10.1007/s00431-003-1340-6.
- 28I. Badiu Tișa, A. C. Achim, and A. Cozma-Petruț, “The Importance of Neonatal Screening for Galactosemia,” Nutrients 15, no. 1 (2023): 10, https://doi.org/10.3390/nu15010010.
- 29N. Hatam, M. Askarian, S. Shirvani, and E. Siavashi, “Neonatal Screening: Cost-Utility Analysis for Galactosemia,” Iranian Journal of Public Health 46, no. 1 (2017): 112–119.
- 30M. A. Kotb, L. Mansour, and R. A. Shamma, “Screening for Galactosemia: Is There a Place for It?,” International Journal of General Medicine 12 (2019): 193–205, https://doi.org/10.2147/IJGM.S180706.
- 31M. Moody, M. Hosseini, A. Deezagi, P. Yaghmaei, and S. M. Houshmand, The Genetic Basis of Galactosemia in Iranian Patients: Identification of Twenty Novel Mutations in GALT, GALK1 and GALE Gene Published online June 26, 2023, https://doi.org/10.21203/rs.3.rs-3093450/v1.
10.21203/rs.3.rs?3093450/v1 Google Scholar
- 32Y. c. Wang, L. c. Lan, X. Yang, J. Xiao, H. x. Liu, and Q. w. Shan, “A Case Report of Classic Galactosemia With a GALT Gene Variant and a Literature Review,” BMC Pediatrics 24, no. 1 (2024): 352, https://doi.org/10.1186/s12887-024-04769-0.
- 33S. Senemar, A. H. Ganjekarimi, S. Senemar, B. Tarami, and M. Bazrgar, “The Prevalence and Clinical Study of Galactosemia Disease in a Pilot Screening Program of Neonates, Southern Iran,” Iranian Journal of Public Health 40, no. 4 (2011): 99–104.
- 34M. Alieh, P. Narjes, K. Zohreh, et al., “The Incidence and Clinical Study of Galactosemia in Fars Province in South of Iran (Short Communication),” Galen Medical Journal 3, no. 1 (2014): 39–45, https://sid.ir/paper/332565/en.
- 35M. Shakiba, M. Yasaei, H. Saneifard, et al., “Expanded Inherited Metabolic Diseases Screening by Tandem Mass Spectrophotometry: The First Report From Iran,” Molecular Genetics and Metabolism Reports 40 (2024): 101103, https://doi.org/10.1016/j.ymgmr.2024.101103.
- 36M. M. Welsink-Karssies, S. Ferdinandusse, G. J. Geurtsen, et al., “Deep Phenotyping Classical Galactosemia: Clinical Outcomes and Biochemical Markers,” Brain Communications 2, no. 1 (2020): fcaa006, https://doi.org/10.1093/braincomms/fcaa006.
- 37B. Delnoy, A. I. Coelho, and M. E. Rubio-Gozalbo, “Current and Future Treatments for Classic Galactosemia,” Journal of Personalized Medicine 11, no. 2 (2021): 75, https://doi.org/10.3390/jpm11020075.
- 38L. A. Batey, C. K. Welt, F. Rohr, et al., “Skeletal Health in Adult Patients With Classic Galactosemia,” Osteoporosis International 24, no. 2 (2013): 501–509, https://doi.org/10.1007/s00198-012-1983-0.
- 39A. B. Frederick, A. M. Zinsli, G. Carlock, K. Conneely, and J. L. Fridovich-Keil, “Presentation, Progression, and Predictors of Ovarian Insufficiency in Classic Galactosemia,” Journal of Inherited Metabolic Disease 41, no. 5 (2018): 785–790, https://doi.org/10.1007/s10545-018-0177-0.
